Jae H. Seo

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.

Journal: International journal of molecular medicine

Published: August 11, 2025

C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBC.

C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBC.

Journal: Oncology reports

Published: July 14, 2025

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer.

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer.

Journal: Experimental hematology & oncology

Published: April 14, 2025

Corrigendum to "Discovery of indazole inhibitors for heat shock protein 90 as anti-cancer agents" [Eur. J. Med. Chem. (2024) 116620].

Corrigendum to "Discovery of indazole inhibitors for heat shock protein 90 as anti-cancer agents" [Eur. J. Med. Chem. (2024) 116620].

Journal: European journal of medicinal chemistry

Published: December 25, 2024

Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.

Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.

Journal: Expert opinion on biological therapy

Published: April 26, 2024

Discovery of indazole inhibitors for heat shock protein 90 as anti-cancer agents.

Discovery of indazole inhibitors for heat shock protein 90 as anti-cancer agents.

Journal: European journal of medicinal chemistry

Published: March 17, 2024

The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.

The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.

Journal: Theranostics

Published: December 14, 2023

Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.

Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 27, 2023

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 28, 2023

Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.

Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.

Journal: Nature communications

Published: July 13, 2023

A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis.

A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: May 15, 2023

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase.

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase.

Journal: Cellular and molecular life sciences : CMLS

Published: August 19, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026